• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

AbbVie axes midstage Alzheimer's program amid 'evolving landscape'

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 25, 2024 at 11:32: AM
via AbbVie is discontinuing solo development of a midstage Alzheimer’s disease candidate, a monoclonal antibody that failed to differentiate itself against already approved treatments.

article source
 




Top Bottom
Back
Quote